SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
The Burkitt leukemia (or acute lymphocytic leukemia FAB L-3) tends to involve the CNS at diagnosis or early during the disease course.
Highly aggressive NHL presenting as acute leukemia; historically classified as small non-cleaved cell lymphoma with solid tumor or nodal mass, as L3 acute lymphoblastic leukemia with > 25% bone marrow involvement. Lymphoma/leukemia recognized as single entity by WHO on basis of shared molecular/genetic features.
The leukemic variant of Burkitt is rare. Only the peripheral blood and bone marrow are involved; there is no lymphadenopathy or bulky disease. CNS tends to be involved at diagnosis or early in the disease process. Burkitt lymphoma is chemosensitive which easily leads to acute tumor lysis syndrome (massive tumor break-down causing sepsis).
Definitive Diagnostic Methods
Bone Marrow biopsy
Peripheral blood smear
t(8;14) in 80%, t(2;8)(p12;q24) or t(8;22)(q24:q11) in 20%